drugset / Trial / NCT04715646

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

NCT04715646

Phase 3 Recruiting 70 enrolled UCB Biopharma SRL
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.

Timeline

Start
2021-03-11
Primary completion
2030-07-08
Completion
2030-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule 1 mg/kg Oral
Subject Brivaracetam Small molecule 4 mg/kg Oral
Subject Brivaracetam Small molecule 5 mg/kg Oral
Subject Brivaracetam Small molecule 200 mg Oral

Indications